The landscape of autoimmune drugs is full of products that work by suppressing the immune system — an approach that works but also comes with complications. Nilo Therapeutics is taking a different tack, developing what it describes as a new class of medicines that tap into the circuitry of the body to bring the immune system back to a state of balance. On Wednesday, the startup revealed some details about its approach along with $101 million to support its work.

New York-based Nilo is building on research into the interactions between the brain and the immune system. The startup is focusing on neural circuits , groups of neurons in the central nervous system that together process specific types of information. Nilo aims to drug neural circuits that control systemic inflammation.

Nilo

See Full Page